Abstract
Juvenile Huntington’s disease (JHD) is usually defined as Huntington’s disease with an onset ≤ 20 years. The proportion of JHD cases reported in studies of Huntington’s disease (HD) varies. A review of the literature found 62 studies that reported the proportion of JHD cases amongst all HD cases. The proportion of JHD cases in these studies ranged from 1% to 15%, and in a meta-analysis the pooled proportion of JHD cases was 4.92% (95% confidence interval of 4.07% to 5.84%). Limiting the analysis to the 25 studies which used multiple methods of ascertainment resulted in a similar pooled proportion of 5.32%, (95% confidence interval 4.18% to 6.60%).
A small difference was observed when the meta-analysis was restricted to studies from countries defined by the World Bank as high income, that used multiple methods of ascertainment, and that were conducted since 1980 (4.81%, 95% confidence interval 3.31% to 6.58%, n=11). This contrasts with the pooled result from three post 1980 studies using multiple methods of ascertainment from South Africa and Venezuela, defined by the World Bank as upper middle income, where the estimated mean proportion was 9.95%, (95% confidence interval 6.37% to 14.22%).
These results, which are expected to be more robust than those from a single study alone, may be helpful in estimating the proportion of JHD cases in a given population.
Key Words: Juvenile Huntington’s disease, prevalence, epidemiology
Funding Statement
Mark Strong and Oliver Bandmann, University of Sheffield; Oliver Quarrell and Kirsty L O’Donovan, Sheffield Children’s NHS Trust.Introduction
Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder with onset usually, but not exclusively, between 35 and 50 years of age1 . Onset ? the age of 20 is classified as juvenile onset Huntington’s disease (JHD), which can be further divided into childhood (0-10 years) and adolescent (11-20 years) onset. Although there are many similarities with the adult form of the disease, JHD has a clinically distinct presentation; the dominant motor feature being a parkinsonian type syndrome of rigidity, dystonia and bradykinesia, rather than chorea234 . In addition, childhood cases may also present with cerebellar signs, epilepsy, myoclonus and spasticity56 . Behavioural problems and cognitive decline are also common in JHD46 , with additional features of developmental delay and autism in childhood cases5 .
The causative mutation in HD has been identified as an expanded CAG repeat sequence in the first exon of the HTT gene 7 . A CAG repeat of ? 40 is unequivocally fully penetrant, with CAG repeats of 36-39 showing reduced penetrance8 . JHD is usually associated with a CAG repeat of ? 60 repeats in approximately 50% of cases9 , with childhood onset often exhibiting a repeat size of ? 80510 . However, consistent with findings in adult cases,CAG repeat size does not always correlate with age of onset in JHD5 .
The prevalence of HD is considered to be approximately 4-10 cases per 100,000 in Caucasian populations11but this may be higher15 . Such variability may be accounted for in part by differences in methods of ascertainment, prevalence method used (period or point prevalence) and diagnostic/age of onset criteria. Low prevalence rates of less than 1 case per 100,000 have been reported in Japanese populations1112 . Well developed medical services in Japan mean under-ascertainment is unlikely12.. More recently, Warby et al (2011)16 have summarised prevalence data from around the world and discussed the reasons for low prevalence in some countries. Prevalence in African and American black populations is also considered to be lower than in white populations1718 . However this may represent under-ascertainment12 , with studies employing more extensive methods reporting equivalent rates19 . Juvenile onset HD is considered to be extremely rare, with few clinicians ever seeing more than one case. In 1981, Hayden summarised the prevalence of JHD, expressed as a percentage of the total number of HD cases surveyed11 . Presented by country, a mean of 5.7% of HD cases were found to be of juvenile onset, with a range of 1-9.6%. Childhood onset was rarer than adolescent onset, with means of 1.3% and 4.4%, respectively. These findings are consistent with the widely accepted belief that JHD is indeed a rare form of the disease.
Although Hayden’s work has been the first and only summary of the epidemiology of JHD known to the authors, there are several limitations in combining and interpreting the data in this way to obtain an estimate of the proportion of JHD cases. The first concerns the pooling of data from different types of studies, such as those reporting period with those reporting point prevalence. Secondly, data are included that are published in more than one paper. Furthermore, the Hayden report includes studies which, due to differences in country and year of study, report prevalence in populations with different age-sex structures. This potentially introduces a bias; lower life expectancies artificially raise the proportion of cases with juvenile onset as patients with adult onset are more likely to die prematurely from unrelated causes. The aim of the current study is therefore to update and expand Hayden’s work, exploring the impact of study level factors on the estimated proportion of HD cases with juvenile onset.
Methods
We searched the MEDLINE and EMBASE databases for the period 1981-May 2011. The following search terms were used in the title and abstract field:
Huntington’s AND disease AND Prevalence
Huntington’s AND disease AND Population
Huntington’s AND disease AND Epidemiology*
Huntington’s AND disease AND Incidence
Huntington*AND Prevalence
Huntington*AND Population
Huntington*AND Epidemiology*
Huntington*AND Incidence
Juvenile AND Huntington*
(* indicates searches including unlimited truncations of the target word)
Studies that did not include a defined HD population were excluded. Literature reviews were included if they provided information on the total number of HD cases surveyed. Studies were excluded if they did not include information on ages of onset, number of juvenile cases, or patients with onset before age 21. We only used published data once. Articles not written in English were excluded, the one exception being the German language Panse study20 as it was included in the original Hayden study. For each study, data relating to the total number of HD cases and total number of juvenile cases were extracted. In addition, the number of cases with childhood (onset 0-10 years) and adolescent (11-20 years) was extracted if available. For each study the proportion of HD cases with juvenile onset was calculated and expressed as a percentage.
Sub-group analyses. Studies were subdivided based on methodology, year of publication and country studied. Study methodology was defined as either “multiple methods of ascertainment” or “HD roster/clinic population”. Of these, the most accurate estimates of prevalence were considered to be from studies with multiple methods of ascertainment. Therefore, studies meeting this criterion were used for all further sub-analyses. To account for any biases relating to age-based population structure, studies were further divided by economic status as defined by the World Bank21 . To account for any time related changes in population structure and to gain an accurate estimate of the current prevalence of JHD, the final sub-group analysis was conducted using studies published between 1980 and 2011.
Statistical analysis. Within each sub-group, study results were pooled in a meta-analysis. Proportions were first transformed using the Freeman-Tukey double arc-sin transformation before being combined. A random effects model was assumed for each meta analysis due to the heterogeneity in the study characteristics. For each meta-analysis the I2 value is reported as a measure of statistical heterogeneity. Confidence intervals presented for each individual study were computed using the exact binomial method. All analyses were conducted using the “meta” package in R 2.13.1 22 .
Results
The search criteria produced a total of 1594 articles. Of these, 48 studies met the inclusion criteria. These studies were combined with those reported by Hayden11 , increasing the total number of studies to 59. The study by van Dijk et al2 was excluded as this literature survey was specifically searching for articles with JHD cases and did not define a denominator total HD population. Although the aim of the study was to update Hayden’s work we also included the paper by Julia Bell 1948 23 .
The pooled data presented in the Cameron and Venters paper24 , which originally included data from their own sample (Scotland) plus that of Bickford and Ellison (Cornwall)25and Pleydell (Northamptonshire)2627 , has been disaggregated to recreate counts in the three study populations. No JHD cases were reported in the Bickford and Ellison paper25 and this was therefore excluded. Therefore, only the data from Pleydell2627 and Cameron and Venters24 are included in our review. Although the counts of JHD cases in the Cameron and Venters paper are not explicitly reported, these were deduced by calculating the number of cases reported in the two Pleydell2627studies.
Cases in the Hayden South African study28were categorised by ethnicity into white, mixed and black populations recognising that the white South African population has a mortality distribution similar to that in countries listed as high income, whereas the mixed population has a mortality distribution similar to countries in the upper middle income group (no cases were reported in the black population). To avoid double counting of data in the meta-analysis, the overall total for South Africa was not included. This produced a revised total of 62 studies. A summary of these studies is presented in an appendix.
The results of the meta-analysis are presented as a forest plot in Figure 1. The black population data from Hayden28 were excluded for purposes of the statistical analysis since there were no HD cases reported. The overall pooled proportion of JHD cases was 4.92% (95% confidence interval (CI) 4.07% to 5.84%), with a range of 1-15%.
Fig. 1: Forest plot of all studies used in this anlysis
Sub-analyses. Table 1 below summarises the results of a number of sub-group analyses of the data which are described below.
HD roster or clinic. Thirty-five studies reported data obtained from either a HD roster or clinic population which are summarised in Fig 2. It is possible that a centre which uses a roster approach may have some patients included in different studies but our final analysis was based on studies which used multiple methods of ascertainment (MMA) so this is is less likely to be a problem.
Fig. 2: Forest plot of studies from a roster or clinic
Multiple methods of ascertainment (MMA). There were 25 studies applying MMA summarised in Fig 3.
Fig. 3: Forest plot of studies which used multiple methods of ascertainment (MMA)
Income status. The World Bank21 classification of countries was used to subdivide the studies, the majority (22 studies) came from the high income group. By comparison, three studies came from the upper middle income group, two came from Venezuela1044 and the third study was that of Hayden28, where the data from the White South African population was included in the high income analysis and data from the mixed population was included in the middle income group. Fig 4 summarises these studies from high income countries.
Fig. 4: Forest plot of studies using MMA from high income countries
Post 1980 studies. Of the MMA studies, 14 were published between 1980 and 2011. Ten were conducted in high income and three in the upper middle income. As above, the final study was that of Hayden28, where the data from the white South African population was included in the high income analysis and data from the mixed population was included in the upper middle income group. The forest plot for studies from high income countries is shown in Fig 5 and the forest plot for studies from upper middle income countries is shown as Fig 6.
Summary of Meta-Analyses
Fig. 5: Forest plot of post 1980 studies using MMA from high income countries
Fig. 6: Forest plot of post 1980 studies using MMA from upper middle income countries
Study type
number
Mean
%95%
Confidence
IntervalRange
%
All studies
62
4.92
4.07-5.84
1-15
HD clinic/Roster
35
4.94
3.85-6.16
1-15
Multiple Metods
of Ascertainment
MMA25
5.32
4.18-6.60
1-15
MMA + High Income
22
4.70
3.71-5.80
1-12
MMA + Upper
Middle Income3
9.95
6.37-14.22
6-15
MMA + Post 1980 +
High Income11
4.81
3.31-6.58
1-10
MMA + Post 1980 +
Upper Middle Income3
9.95
6.37- 14.22
6-15
Data on childhood and adolescent onset cases was available for 42 studies, representing 475 cases. Of these, 111 (23.4%) and 364 (76.6%) were childhood and adolescent onset, respectively. Only seven studies found a higher proportion of childhood onset cases, with two studies reporting equal numbers. Therefore in 76% of studies, adolescent onset occurred more frequently than childhood onset. When we consider just the most recent studies of the highest quality from the high income group (the MMA-post 1980 studies), the pattern is similar with 40 out of 50 (80%) cases being of adolescent onset.
Discussion
Main results. In the meta-analysis of all the studies identified in this review we estimate the proportion of JHD cases to be 4.92% (95% CI 4.07% – 5.84%). In order to expand on Hayden’s original work11 and produce more robust estimates of the proportion of JHD cases, the potential sources of bias associated with the various studies were considered. We identified 35 studies which were based on clinic lists or rosters (Figure 2); and 25 studies which used multiple methods of ascertainment (Figure 3). These gave mean estimates of the proportion of 4.94% and 5.32% respectively. A clinic list or roster approach may downwardly bias the proportion of JHD cases if it is perceived that the clinic serves mainly adult patients. Studies with multiple methods of ascertainment are more likely to give a robust estimate.
Most studies were conducted in Europe and North America so the effect of considering geography was minimal (Figure 4); however, the three studies from economically less developed countries (Figure 5) were effectively from the South African black population and Venezuela. The longitudinal study of families from the area around Lake Maricaibo has been important in that it contributed to the original localisation of the gene to chromosome 4 and for an understanding of the natural history of the condition 104480 The mean proportion of JHD cases from these three studies was 9.95% (95% CI 6.57% – 14.22%). If the age of death was lower in the general population in which these cases live, then those with HD who were destined to develop the condition later in life may not manifest as they die of other causes; consequently the proportion of JHD cases will be higher. In addition, the patients with HD living around Lake Maricaibo are a relatively closed community so it is possible that this also has an effect on the proportion of JHD cases. These three studies were reported after 1980.
Eleven studies were reported after 1980, which used multiple methods of ascertainment, and were from economically more developed countries; these gave a slightly lower proportion of 4.81% (95% CI 3.31% – 6.58%) and may be considered the most robust estimate to use when considering European and North American populations.
Implications for Research. At present, there is no treatment to alter the natural history of HD. As soon as treatments become available which do alter the natural history of HD, then it will be important to assess their effects on patients at the more extreme end of the phenotypic spectrum. If a faster rate of disease progression can be demonstrated in this group of patients, then any compound which affects the natural history of HD may show an effect more quickly.
In June 2010, the UK population was estimated to be 62.3 million79 . If we assume the prevalence of HD is approximately 4-10 per 10011121314 , in the UK and we also assume some degree of under-ascertainment; therefore, using a figure of 100 HD patients per million would imply that there are around 6,230 patients with HD in the UK, so we should expect to see approximately 300 cases with an onset under the age of 20 years (95% CI 205 – 411). Identifying these patients represents a considerable challenge.
Conclusion
We have presented a review of the proportion of cases with JHD from 62 studies. Using data from 25 studies after 1980 which were mainly fromNorthern Europe suggests that the mean proportion of JHD cases is just less than 5%.
Appendix 1
| 0 - 10 years | 11-20 years | Total JHD | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Authors | Publication year |
Location | Total HD cases | Number | % | Number | % | Number | % |
| *Davenport & Muncey29 |
1916 | USA | 138 | 3 | 2.2 | 2 | 1.4 | 5 | 3.6 |
| *Spillane & Phillips30 |
1937 | South Wales |
21 | 0 | 0 | 2 | 9.5 | 2 | 9.5 |
| *Panse20 | 1942 | Germany | 446 | 7 | 1.6 | 17 | 3.8 | 24 | 5.4 |
| Pleydell26 | 1954 | England | 17 | 0 | 0 | 2 | 11.8 | 2 | 11.8 |
| *Reed et al18 |
1958 | USA | 203 | 0 | 0 | 12 | 5.9 | 12 | 5.9 |
| *Brothers31 | 1964 | Australia | 206 | 4 | 1.9 | 11 | 5.3 | 15 | 7.3 |
| *Cameron & Venters24 |
1967 | Scotland | 143 | - | - | - | - | 3 | 21 |
| *Heathfield32 | 1967 | England | 81 | 0 | 0 | 2 | 2.5 | 2 | 2.5 |
| *Oliver33 | 1970 | England | 115 | 4 | 3.5 | 7 | 6.1 | 11 | 9.6 |
| *Mattsson34 | 1974 | Sweden | 362 | - | - | - | - | 17 | 4.7 |
| *Stevens35 | 1976 | England | 133 | 0 | 1 | 0.8 | 1 | 0.8 | |
| Walker et al36 | 1981 | South Wales |
333 | 3 | 0.9 | 11 | 3.3 | 14 | 4.2 |
| *Hayden et al28 | 1982 | S Africa Total |
219 | 6 | 2.7 | 11 | 5 | 17 | 7.7 |
| S Africa Whites |
147 | 3 | 2.0 | 3 | 2.0 | 6 | 4.1 | ||
| S Africa Mixed |
72 | 3 | 4.2 | 8 | 11.1 | 11 | 15.3 | ||
| S Africa Blacks |
0 | 0 | 0 | ||||||
| Myers et al37 | 1982 | USA | 83 | 2 | 2.4 | 7 | 8.4 | 9 | 10.8 |
| Went et al38 | 1983 | Netherlands | 276 | 5 | 81. | 3 | 1.1 | 8 | 2.9 |
| Di Maio et al39 | 1984 | Italy | 95 | - | - | - | - | 4 | 4.2 |
| Went et al40 | 1984 | Netherlands | 1246 | 13 | 1.0 | 0 | 0 | 13 | 1.0 |
| Farrer & Conneally41 |
1985 | USA | 569 | 4 | 0.7 | 24 | 4.2 | 28 | 4.9 |
| Hayden et al42 | 1985 | USA | 598 | - | - | - | - | 89 | 14.9 |
| Groppi et al43 | 1986 | Italy | 48 | - | - | - | - | 5 | 10.4 |
| Young et al44 | 1986 | Venezueala | 65 | 1 | 1.5 | 3 | 4.6 | 4 | 6.2 |
| Folstein et al19 | 1987 | USA | 217 | - | - | - | - | 15 | 6.9 |
| Adams et al45 | 1988 | USA | 611 | 5 | 0.8 | 25 | 4.1 | 30 | 4.9 |
| Fromtali et al46 | 1990 | Italy | 299 | 2 | 0.7 | 9 | 3 | 11 | 3.7 |
| Pavomi et al47 | 1990 | Italy | 47 | 0 | 0 | 1 | 3.1 | 1 | 2.1 |
| Pridmore48 | 1990 | Tasmania | 48 | 0 | 0 | 3 | 6.3 | 3 | 6.3 |
| Roos et al49 | 1991 | Netherlands | 632 | - | - | - | - | 12 | 1.9 |
| Leung et al50 | 1992 | China & Hong Kong |
89 | 4 | 4.5 | 0 | 0 | 4 | 4.5 |
| Ridley et al51 | 1992 | USA | 3945 | - | - | - | - | 208 | 5.3 |
| Morrison & Nevin52 |
1993 | N Ireland | 12 | 0 | 0 | 1 | 8.3 | 1 | 8.3 |
| Roos et al53 | 1993 | Netherlands | 1106 | - | - | - | - | 6.5 | 5.9 |
| Simpson et al54 | 1993 | Scotland | 82 | 0 | 0 | 3 | 3.7 | 3 | 3.7 |
| Watt & Seller55 | 1993 | England | 101 | - | - | - | - | 4 | 4.0 |
| Shiwach56 | 1994 | England | 135 | 0 | 0 | 8 | 5.9 | 8 | 5.9 |
| Morrison et al57 | 1995 | N Ireland | 101 | 2 | 2 | 4 | 4 | 6 | 6 |
| Sanchest et al59 | 1996 | Spain | 31 | 0 | 0 | 4 | 12.9 | 4 | 12.9 |
| Alonso et al58 | 1997 | Mexico | 83 | - | - | - | - | 6 | 7.2 |
| Siesling et al4 | 1997 | Netherlands | 2787 | - | - | - | - | 65 | 2.3 |
| Gomez-Totosa et al59 | 1998 | Spain | 81 | 1 | 1.2 | 6 | 7.4 | 7 | 8.6 |
| Atac et al60 | 1999 | Turkey | 27 | 0 | 0 | 2 | 7.4 | 2 | 7.4 |
| Faroud et al61 | 1999 | USA | 2068 | - | - | - | - | 94 | 4.5 |
| Louis et al62 | 1999 | USA | 43 | 0 | 0 | 1 | 2.3 | 1 | 2.3 |
| Lima et al63 | 2000 | Brazil | 30 | 0 | 0 | 3 | 10 | 3 | 10 |
| Raskin et al64 | 2000 | Brazil | 59 | 3 | 5.1 | 4 | 6.8 | 7 | 11.9 |
| Rasmussen et al65 |
2000 | Mexico | 364 | 7 | 1.9 | 18 | 4.9 | 25 | 6.9 |
| Almqvist et al66 | 2001 | Canada | 102 | 0 | 0 | 2 | 2 | 2 | 2.0 |
| Murgod et al68 | 2001 | India | 26 | - | - | - | - | 4 | 15.4 |
| Maat Kievit et al68 | 2002 | Netherlands | 755 | - | - | - | - | 18 | 3.0 |
| Akbas Erginel-Unaltuna69 |
2003 | Turkey | 127 | 1 | 0.8 | 7 | 5.5 | 8 | 6.3 |
| Creighton et al71 | 2003 | Canada | 282 | - | - | - | - | 5 | 1.8 |
| do Como Costa et al72 |
2003 | Portugaul | 120 | 3 | 2.5 | 1 | 0.8 | 4 | 3.3 |
| Cannella et al73 | 2004 | Italy | 524 | 5 | 1 | 52 | 9.9 | 57 | 10.9 |
| Wexler et al10 | 2004 | Venezueala | 443 | - | - | - | - | 40 | 9.0 |
| Ramos-Aroyo et al74 |
2005 | Spain | 112 | - | - | - | - | 7 | 6.3 |
| Ruocco et al74 | 2006 | Brazil | 50 | 2 | 4 | 2 | 4 | 4 | 8.0 |
| Ribai et al6 | 2007 | France | 1453 | 8 | 0.6 | 21 | 1.4 | 29 | 2.0 |
| Zidovska et al76 | 2007 | Czech Republic |
411 | - | - | - | - | 12 | 2.9 |
| Van Duijn et al77 | 2008 | Netherlands | - | - | - | - | - | 1 | 0.6 |
| Alonso et al78 | 2009 | Mexico | 691 | 16 | 2.3 | 41 | 5.9 | 57 | 8.2 |
| Torres et al79 | 2010 | Peru | 131 | - | - | - | - | 9 | 6.9 |
References
- Orth, Michael; Schwenke, Carsten. Age-at-onset in Huntington disease [Internet]. Version 10. PLoS Currents: Huntington Disease. 2011 Jul 1 [revised 2011 Jul 29]. Available from: https://knol.google.com/k/michael-orth/age-at-onset-in-huntington-disease/3dua5u7tnja1b/3.
- van Dijk JG, van der Velde EA, Roos RAC, Bruyn GW. Juvenile Huntington’s disease. Hum Genet 1986;73:235-39.
- Barker RA, Squitieri F. The clinical phenotype of juvenile Huntington’s disease. In: Quarrell OWJ, Brewer HM, Squitieri F, Barker RA, Nance MA, Landwehrmeyer BG, eds. Juvenile Huntington’s Disease and Other Trinucleotide Repeat Disorders. New York: Oxford University Press; 2009.
- Siesling S, Vegter-van der Vlis M, Roos RAC. Juvenile Huntington disease in the Netherlands. Paed Neurol 1997;17:37-43.
- Squitieri F, Frati L, Ciarmiello A, Lastoria S, Quarrell O. Juvenile Huntington’s disease: Does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev 2006;127:208-212.
- Ribai P, Nguyen K, Hahn-Barma V, et al. Psychiatric and cognitive difficulties as indicators of juvenile Huntington disease onset in 29 patients. Arch Neurol 2007;64:813-19.
- The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-83.
- ACMG/ASHG. ACMG/ASHG Statement. Laboratory guidelines for Huntington’s disease genetic testing. Am J Hum Genet 1998;62:1243–7
- Quarrell OWJ, Nance MA. The diagnostic challenge. In: Quarrell OWJ, Brewer HM, Squitieri F, Barker RA, Nance MA, Landwehrmeyer BG, eds. Juvenile Huntington’s Disease and Other Trinucleotide Repeat Disorders. New York: Oxford University Press; 2009.
- The U.S.–Venezuela Collaborative Research Project and Wexler N. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset. Proc Natl Acad Sci U S A 2004;101:3498-503.
- Hayden MR. Huntington’s Chorea. Berlin: Springer-Verlag; 1981
- Harper PS. The epidemiology of Huntington’s disease. Hum Genet 1992;89:365-76.
- Morrison PJ, Harding-Lester S, Bradley A. Uptake of Huntington’s disease testing in a complete population. Clin Gen 2011;80:281-6.
- Hoppitt T, Calvert M, Pall H, Rickards H, Sackley C. Huntington’s disease. Lancet 2010;376:1463-4.
- Rawlins M. Huntington’s disease out of the closet? Lancet 2010;376:1372-3.
- Warby SC, Visscher H, Collins JA, Doty CN et al. HTT haplotypes contribute to differences in Huntington’s disease prevalence between Europe and Eas Asia Europ J Hum Genet 2011; 19:561-566.
- Hayden MR, MacGregor, JM, Beighton, PH. The prevalence of Huntington’s Chorea in South Africa. S Afr Med J 1980;58:193-6.
- Reed TE, Chandler JH, Hughes EM, Davidson RT. Huntington’s Chorea in Michigan: Demography and genetics. Am J Hum Genet 1958;10:201-25.
- Folstein SE, Chase GA, Wahl WE, McDonnell AM, Folstein, MF. Huntington disease in Maryland: clinical aspects of racial variation. Am J Hum Genet 1987;41:168-79.
- Panse F. Die Erbchorea: Eine klinische-genetische studie. Samml Psychiatr Neurol Einzeldarst, 18. Leipzig: Thieme; 1942.
- The World Bank. Country Classifications, 2012. Available from https://data.worldbank.org/about/country-classifications.
- R Development Core Team (2011). R: A Language and Environment for Statistical Computing, R Foundation for Statistical Computing, Vienna, Austria, ISBN 3-900051-07-0.
- Bell J. Nervous Diseases and Muscular Dystrophies. In: Fisher RA, Penrose S, eds. The Treasury of Human Inheritance. Vol IV. Cambridge: Cambridge University Press, pp.1-69; 1948.
- Cameron D, Venters GA. Some problems in Huntington’s chorea. Scott Med J. 1967;12(4):152-6.
- Bickford JAR, Ellison RM. The high incidence of Huntington’s chorea in the Duchy of Cornwall. J Ment Sci. 1953;99(415):291-4.
- Pleydell MJ. Huntington’s chorea in Northamptonshire. Br Med J. 1954;2(4897):1121-8.
- Pleydell MJ. Huntington’s chorea in Northamptonshire. Br Med J. 1955;2(4944):889.
- Hayden MR, MacGregor JM, Saffer DS, Beighton PH. The high frequency of juvenile Huntington’s chorea in South Africa. J Med Genet. 1982;19(2):94-7.
- Davenport CB, Muncey, EB. Huntington’s Chorea in relation to history and eugenics. Am J Insan. 1916;73:195-222.
- Spillane J, Phillips R. Huntington’s Chorea in South Wales. Q J Med. 1937;6:403-423.
- Brothers CR. Huntington’s Chorea in Victoria and Tasmania. J Neurol Sci. 1964;1:405-420.
- Heathfield KWG. Huntington’s chorea: Investigation into the prevalence of this disease in the area covered by the North East Metropolitan Regional Hospital Board. Brain. 1967;90:203-232.
- Oliver JE. Huntington’s chorea in Northamptonshire. Br J Psychiatry. 1970;116:241-253.
- Mattsson B. Clinical, genetic and pharmacological studies in Huntington’s chorea. UMEA University Medical Dissertations 7. Sweden: UMEA:21-51; 1974.
- Stevens DL. Huntington’s chorea: a demographic, genetic and clinical study. MD thesis, University of London, pp. 1-338; 1976.
- Walker DA, Harper PS, Wells CEC, Tyler A, Davies K, Newcombe RG. Huntington's Chorea in South Wales A genetic and epidemiological study. Clin Gen. 1981;19(4):213–221.
- Myers RH, Madden JJ, Teague JL, Falek A. Factors related to onset age of Huntington disease. Am J Hum Genet. 1982;34(3):481-8.
- Went LN, Vegter-van der Vlis M, Bruyn LW, Vlkers WS. Huntington's chorea in the Netherlands - The problem of genetic heterogeneity. Ann Hum Genet 1983;47(3):205-14
- Di Maio L, Mengano A, Maggio MA, Michele G De, Campanella G. Paternal and maternal transmission in Huntington’s disease. Acta Neurol. 1984;6(6):447-50.
- Went LN, Vegter-van der Vlis M, Bruyn GW. Parental transmission in Huntington’s disease. Lancet. 1984;1(8386):1100-2.
- Farrer LA, Conneally PM. A genetic model for age at onset in Huntington disease. Am J Hum Genet. 1985;37(2):350-7.
- Hayden MR, Soles JA, Ward RH. Age of onset in siblings of persons with juvenile Huntington disease. Clin Gen. 1985;28(2):100-5.
- Groppi C, Barontini F, Bracco L, et al. Huntington’s chorea: a prevalence study in the Florence area. Acta Neurol Scand. 1986;74(4):266-8.
- Young AB, Shoulson I, Penney JB, et al. Huntington’s disease in Venezuela: neurologic features and functional decline. Neurol. 1986;36(2):244-9.
- Adams P, Falek A, Arnold J. Huntington disease in Georgia: age at onset. Am J of Hum Genet. 1988;43(5):695-704.
- Frontali M, Malaspina P, Rossi C, et al. Epidemiological and linkage studies on Huntington’s disease in Italy. Hum Genet. 1990;85(2):165-70.
- Pavoni M, Granieri E, Govoni V, et al. Epidemiologic approach to Huntington’s disease in northern Italy (Ferrara area). Neuroepidemiology. 1990;9(6):306-14.
- Pridmore SA. Age of onset of Huntington’s disease in Tasmania. Med J Aust. 1990;153(3):135-7.
- Roos RA, Vegter-van der Vlis M, Hermans J, et al. Age at onset in Huntington’s disease: effect of line of inheritance and patient's sex. J Med Genet. 1991;28(8):515-9.
- Leung CM, Chan YW, Chang CM, Yu YL, Chen CN. Huntington’s disease in Chinese: a hypothesis of its origin. J Neurol, Neurosurg, and Psychiatry. 1992;55(8):681-4.
- Ridley RM, Farrer LA, Frith CD, Conneally PM. A test of the hypothesis that age at onset in Huntington disease is controlled by an X-linked recessive modifier. Am J Hum Genet. 1992;50(3):536-43
- Morrison PJ, Nevin NC. Huntington disease in County Donegal: epidemiological trends over four decades. Ulster Med J. 1993;62(2):141-4
- Roos RA, Hermans J, Vegter-van der Vlis M, Ommen GJ van, Bruyn GW. Duration of illness in Huntington’s disease is not related to age at onset. J Neurol Neurosurg Psychiatry. 1993;56(1):98-100.
- Simpson SA, Davidson MJ, Barron LH. Huntington’s disease in Grampian region: correlation of the CAG repeat number and the age of onset of the disease. J Med Genet. 1993;30(12):1014-7.
- Watt DC, Seller A. A clinico-genetic study of psychiatric disorder in Huntington’s chorea. Psychol Med. 1993;Suppl 23:1-46.
- Shiwach RS. Prevalence of Huntington’s disease in the Oxford region. Br J Psychiatry : J Ment Sci. 1994;165(3):414-5.
- Morrison PJ, Johnston WP, Nevin NC. The epidemiology of Huntington’s disease in Northern Ireland. J Med Genet. 1995;32(7):524-30.
- Alonso ME, Yescas P, Cisneros B, et al. Analysis of the (CAG)n repeat causing Huntington’s disease in a Mexican population. Clin Gen. 1997;51(4):225-30.
- Gómez-Tortosa E, Barrio A del, García Ruiz PJ, et al. Severity of cognitive impairment in juvenile and late-onset Huntington disease. Arch Neurol. 1998;55(6):835-43
- Ataç FB, Elibol B, Schaefer F. The genetic analysis of Turkish patients with Huntington’s disease. Acta Neurol Scand. 1999;100(3):195-8.
- Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington’s disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999;66(1):52-6
- Louis ED, Lee P, Quinn L, Marder K. Dystonia in Huntington’s disease: prevalence and clinical characteristics. Mov Disord. 1999;14(1):95-101.
- Lima E Silva TC, Serra HG, Bertuzzo CS, Lopes-Cendes I. Molecular diagnosis of Huntington disease in Brazilian patients. Arq Neuropsiquiatr. 2000;58(1):11-7.
- Raskin S, Allan N, Teive HA, et al. Huntington disease: DNA analysis in Brazilian population. Arq Neuropsiquiatr. 2000;58(4):977-85.
- Rasmussen A, Macias R, Yescas P, et al. Huntington disease in children: genotype-phenotype correlation. Neuropediatrics. 2000;31(4):190-4.
- Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia. Clin Gen. 2001;60(3):198-205.
- Murgod UA, Saleem Q, Anand A, et al. A clinical study of patients with genetically confirmed Huntington’s disease from India. J Neurol Sci. 2001;190(1-2):73-8.
- Maat-Kievit A, Losekoot M, Zwinderman K, et al. Predictability of age at onset in Huntington disease in the Dutch population. Medicine. 2002;81(4):251-9.
- Akbas F, Erginel-Unaltuna N. DNA testing for Huntington disease in the Turkish population. Eur Neurol. 2003;50(1):20-4.
- Creighton S, Almqvist EW, MacGregor D, et al. Predictive, pre-natal and diagnostic genetic testing for Huntington’s disease: the experience in Canada from 1987
- do Camo Costa M, Magalhães P, Ferreirinha F, et al. Molecular diagnosis of Huntington disease in Portugal: implications for genetic counselling and clinical practice. Eur J Hum Genet:2003;11(11):872-8.
- Cannella M, Gellera C, Maglione V, et al. The gender effect in juvenile Huntington disease patients of Italian origin. American journal of medical genetics. Part B, Am J Med Genet B Neuropsychiatr Genet. 2004;125B(1):92-8.
- Ramos-Arroyo MA, Moreno S, Valiente A. Incidence and mutation rates of Huntington’s disease in Spain: experience of 9 years of direct genetic testing. J Neurol Neurosurg Psychiatry. 2005;76(3):337-42.
- Ruocco HH, Lopes-Cendes I, Laurito TL, Li LM, Cendes F. Clinical presentation of juvenile Huntington disease. Arq Neuropsiquiatr 2006;64(1):5-9
- Židovská J, Klempíř J, Kebrdlová V, et al. Huntington’s Disease: Experience with Genetic Testing within 1994–2005. Cesk Slov Neurol N 2007; 70/103(1): 72–77
- van Duijn E, Kingma EM, Timman R, et al. Cross-sectional study on prevalences of psychiatric disorders in mutation carriers of Huntington’s disease compared with mutation-negative first-degree relatives. J Clin Psychiatry. 2008;69(11):1804-10.
- Alonso ME, Ochoa A, Boll M-C, et al. Clinical and genetic characteristics of Mexican Huntington’s disease patients. Movement. 2009;24(13):2012-5
- Torres G, Timana C, Cornejo M, et al. Molecular diagnosis of Huntington’s disease in Peruvian population. Mov Disord. 2010;25(Suppl. 2):S278
- Office for National Statistics. Annual Mid-year Population Estimates, 2010. Available at: https://www.ons.gov.uk/ons/taxonomy/index.html?nscl=Population+Estimates. Accessed September 16, 2011.
- Gusella JF , Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, Watkins PC, Ottina K, Wallace MR, Sakaguchi AY ( 1983) A polymorphic DNA marker genetically linked to Huntington’s disease . Nature.1983 Nov 17-23; 306(5940):234-8.
Leave a Comment
You must be logged in to post a comment.